Board of Directors

Graham Cole CBE

Board Chair and Non-Executive Director

Graham was appointed to the Board on 13th July 2026. Over more than four decades he has held leadership, board and governance roles across the advanced engineering, manufacturing and technology sectors. He previously served as Chairman of Westland Helicopters and held a number of senior executive positions within the AgustaWestland Group. He also served on the Board of parent company Finmeccanica UK and has held a range of non-executive and advisory positions across industry. In addition, Graham has served on several UK Government ministerial committees. In 2024 he was appointed a Commander of the Order of the British Empire (CBE) for services to the aerospace industry and holds Freedom to the City of London.

Gino Miele

Ph.D., Chief Executive Officer, Chief Scientific Officer

Gino was appointed Chief Executive Officer on 6th August 2024 and a Director and Chief Scientific Officer on 11th September 2023. He has considerable experience in the development of molecular diagnostic technologies and instrumentation, and has been the R&D Director at genedrive since 2015 and its predecessor Epistem since 2011. Prior to that Gino served as Associate Director for clinical translational genomics at Wyeth and Pfizer. Gino has been a key driver in the development of the genedrive® system and positioning of point of care pharmacogenetic testing in emergency healthcare.

Russ Shaw

Chief Financial Officer

Russ was appointed Chief Financial Officer on 7th April 2022. He has over 25 years of international experience across multiple sectors including life-sciences, technology and the industrials. Prior to joining genedrive, he spent 10 years as Finance Director at Driver Group plc, an AIM quoted company operating in the engineering and construction industry. Russ has been CFO of several private companies in recent years and is a qualified Accountant and Treasury professional.

Chris Yates

Non-executive Director, Chairman of the Audit Committee

Chris was appointed to Board on 22 August 2018. He is currently CEO of Abingdon Health plc, a position he has held since July 2015. Chris co-founded Abingdon in 2008 and was a non-executive of the company prior to his appointment as CEO. Chris has over 20 years experience of working in listed environments and prior to working at Abingdon, was CFO at Immunodiagnostic Systems Holdings PLC and Cozart plc. Chris is a Chartered Accountant and has a degree in economics from Cambridge University.

David Nugent

Non-Executive Director

David was appointed to Board on 26 May 2026. He is a UK-based serial entrepreneur, private investor and strategic backer of growth-stage companies. David is the founder and director of a number of private businesses, reflecting a broad background in entrepreneurship and private investment across multiple sectors and is the largest shareholder in the Company.